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There was also a strong correlation between Eh GSH/GSSG and CIMT (I = 0.60, p- < 
0.01). and an inverse correlation between GSH and CIMT (I = - 0.52, p- < 0.01). We then 
stratified subjects based on their CIMT Into those with CIMT > 0.6 mm and those with 
CIMT ( 0.6”“. Differences in the varws markers between the 2 groups are shown 
below. 
Variable (Units) CIMT so.60 mm CIMT > 0.60 mm P-value 
FMD (%) 7.68% (+/-2.4) 5.59% (+/- 3.1) 0.02 
Eh GSHiGSSG (mV) -126.2 (+/- 6.3) -118.8 (+/- 7.2) 0.01 
GSH (uM) 2.51(+/-0.86) 1.84 (+i- 0.69) 0.03 
GSSG (uM) 0.24 (+/-0.11) 0.23 (+/- 0.12) NS 
After multivariate analysis, both FMD and Eh GSHiGSSG were independent predictors of 
CIMT. Conclusion: These flndings suggest that markers of oxidative stress such as Eh 
GSH/GSSG may be helpful in predicting individuals at risk for early atherosclerosis. This 
predictive value appears to be independent of endothelial function. 
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1177-126 Additive Effects of Angiotensin Converting Enzyme 
inhibitor Combined With Statin on Inflammation and 
Fibrinolysis in Hypercholesterolemic Patients With 
Coronary Artery Disease 
Kwang K. Koh. Ji W. Son, Jeong Y. Ahn, Mi-Seunq Shin, In S. Char, Eak K. Shm, 
Gachon Medical School, Incheon, South Korea 
Background: Because the mechanisms of the biological effects of statins and antio- 
tensln converting enzyme inhibitor therapies differ, we studied the vascular responses to 
these therapies in hypercholesterolemic patients with coronary artery disease (CAD). 
Methods: We administered simvastatin 20 mg and placebo or ramipril 10 mg daily during 
2 months with washout 2 months to 30 hypercholesterolemic patients with CAD. This 
study was randomized, double-blind, placebo-controlled, crcsscver in design. 
‘=P~0.05;~‘=Pc0.01;*“=Pc0.001 vs. Baseline. Data= mean+SD. 
Results: Slmvastatin alone or combined with ramipril significantly changed lipoproteins. 
and improved the percent flow-mediated dilator response (FMD) to hyperemia from 
4.57k1.63 to 5.96+1.88 by 38+40% and from 4.49+1.39 to’ 6.28+1.76 by 53*77%, 
respectively (both P<O.OOl) and reduced plasma levels of nitrate from 97r47 to 90*52 
uM by 4*58% and from 97+47 to 79*44 uM by 10*47%, respectively (P~O.413 and 
P=O.O37, respectively), and plasma levels of malondlaldehyde (MDA), a marker of free 
radical from 1.41iO.66 to 1 .l lr0.60 uM by 13+44% and from 1.4OkO.79 to 0.97iO.57 uM 
by 20*48%, respectively (P=O.O05 and P<O.OOl, respectively), and MCP-1 by 7*24% 
and by 13*18%. respectively (P=O.OiO and P<O.OOl, respectively), and C-reactive pro- 
tein by -7*107% and by 15+45%, respectively (P=O.O73 and P=O.O09, respectwely) , and 
PAI- antigen by -9*52% and by 11+38%, respectively (P=O.971 and P=O.O14, respec- 
tively). However, simvastatin combmed with ramlpril changed to greater extent FMD, and 
plasma levels of nitrate. MDA, MCP-1, CRP, and PAI- antigen than simvastatin alone. 
Conclusions: Compared with slmvastatin alone, added ramipril to simvastatin showed 
additive effects on flow-mediated dilation and the plasma levels of nitrate and MDA, 
inflammation markers and fibrinolysls potential markers in hypercholesterolemic patients 
with CAD. 
1177-l 27 In Vivo Evidence for Adriamycin-Induced Uncoupling of 
Endothelial Nitric Oxide Synthase 
Damon Duquaine, Glenn Hirsch, Anjan Chakrabarti, B. Kalayanaraman, Joy Joseph, 
Christine Kehrer, Robert D. Brook, Jeanette Vasquez-Vivar, Sanjay Rajagopalan, 
University of Michigan. Ann Arbor, Ml 
Background: Adriamycin (ADR) IS a commonly used anti-neoplastic agent that IS well 
known to induce cardiotoxlclty. While the mechanisms of this effect are not entirely clear, 
evidence suggests that it is a free radical medlated process. We hypothewed that 
administration of a single dose of ADR is associated with abnormalities in nitric oxide 
PNO) availability and endothelial nttrlc oxide synthase related superoxide (O& genera- 
tion. 
Methods and results: A single dose of ADR (10 mgikg IV) in rabbits resulted I” reduced 
peak relaxations to the agonists acetylcholine (Ach, 99&Z% to 57*4%) and A23187 
(92*3% to 57+5%) and a shift in the ED, values. Peak relaxations to NTG were also 
altered (104+1 to 60*6) with no change I” ED, concentration. Exposure of aortic seg- 
ments to ADR for 30 minutes resulted in dose dependent 9: generation, as measured 
by electron spin resonance (ESR) that was abolished by endothelial denudation and 
incubation with diphenylene-iodinuim (IOpM) but not L-NMMA (l@M). Experiments with 
recombinant eNOS protein, conflrmed a dose dependent decrease in *NO generation as 
measured by L-Arginme-Citrulline assays and increase in 0,; production with ADR. Bra- 
chial artery flow medlated dilation (FMD) in patients undergolng ADR administration (60 
“s/m*) was markedly attenuated after a single dose (6.5*1.0 to 2.5+1.1%, p=O.O004, 
time to end of infusion 27+8 minutes). Serum nitrite and nitrate concentrations fell from 
50+6 pmol/L pre-ADR to 33r6 pmol/L post ADR infusion (p=O.O005) while serum con- 
centrations of CD/131 thrombomodulin and vWF activity remained unchanged after ADR 
Infusion (36i13 to 52*22% ng/ml vs. 3.25*0.96 to 3.01+0.91% (p=NS for pre vs. post for 
both). 
Conclusions ADR administration results in rapid depletion of *NO levels as ewdenced 
by attenuation of agonist dependent responses in rabbits and reactive hyperemic 
responses in human brachial arteries associated with reductions in serum *NO levels. 
ESR measurements in aortic segments strongly suggest an eNOS origin for free radical 
production. These findings may have implications for cardiovascular complications noted 
wti ADR. 
1177-126 Lipophilic Statin-Induced Antiangiogenesis Requires 
the inhibition of Ras Farnesylation in Human Coronary 
Artery Endothelial Cells 
Shin-ichiro Miura Masahiro Fujino, Yoshino Matsuo, Hiroaki Nishlkawa. Keijiro Saku, 
Fukuoka University, Fukuoka. Japan 
Background: While a recent report suggested that inhibition of Ras might be an effective 
anti-angiogenic therapy, it is unclear whether Ras mediates 3.hydroxy-3-methylglutatyl 
coenzyme A reductase Inhibitor (statin).induced signal transduction. Therefore, we 
investigated that Ras plays a role in statin-mediated promotion of angiogenesis I” human 
coronary artery endothelial cells (HCECs). 
Methods: We developed an in vitro model of HCECs tube formation on a matrix gel. 
pEGFP(enhanced green fluorescent protein)-wild type (WT) Ras and pEGFP-dominant 
negative (N17) Ras expression vectors were constructed. Untransfected or transfected 
HCECs were seeded on a matrix gel and grown in medium supplemented with 5 % 
serum and without endothelial cell growth supplement for 24 hours. In some experi- 
mews, cells were cultured in the presence or absence of different kinds of reagents. 
Results: Lipophlllc statins (slmvastatln, atrovastatm, itavastatln and cerivastatin), but not 
a hydrophilic statin (pravastatin), inhibited serum-induced endothelial tube formation. 
lnhibltion of p42/44 MAPK (mitogen-actwated protein kinase) activity, but not the inhibl- 
tion of ~38 MAPK actwity, also suppressed serum-Induced tube formation. The addition 
of mevalonic acid rescued simvastatin-Induced inhibition. Farnesylpyrophosphate, which 
translocates Ras from the cytoplasm to the cell membrane, also blocked this inhibition. In 
addition, farnesyltransferase I inhibitor, which inhibits Ras farnesylation, blocked tube 
formation. RasN17 also inhibited serum-induced tube formation. Moreover, simvastatin 
blocked epidermal growth factor-induced EGFP-R&NT translocation. 
Conclusions: Our results Identified Ras as a key player in the anti-angiogenic action and 
signaling pathway of statins. This is the first comprehensive analysis af the role of Ras in 
the s&tin-induced modulation of an angiogenic effect. The inhibition of angiogenesis by 
statin could explain, at least in part. the protective effect of these drugs against athero- 
thrombotlc events. which was greater than expected simply based on the cholesterol 
decrease. 
1177-129 Angiotensin II Type-l Receptor Antagonist Inhibits 
Vascular Phenotypic Change and Remodeling in 
lntramyocardial Arteries by Reducing Oxidative Stress 
Through Upregulation of Superoxide Dismutase 
Masakazu Tanaka, Seiji Umemoto, Shinji Kawahara, Kyoko Umeji, Masunori Matsuzaki, 
Yamaguchi University Graduate School of Medicine, Ube, Japan, Pharmaceutical 
Clinical Research Center, Yamaguchi University Hospital, Ube, Japan 
Background: Angiotensin II type-l receptor antagonists reduce reactive oxygen species 
(ROS) generated by activated NAD(P)H oxidase and vascular remodeling in hyperten- 
slon, however, the effect of ARAs on the scavenging enzymes related to ROS is unclear. 
We have examined whether Angiotensin II type-l receptor antagonists may inhibit vsscu- 
lar remodeling and smooth muscle (SM) cell phenotypic change in intramyocardial artar- 
es via ROS-scavenging enzymes. 
Methods: Male stroke-prone SHR (SHRSP) were randomized and treated for 6 weeks 
with vehicle, AIIA (E4177; 30 “g/kg/day), or angiotensln-converting enzyme (ACE) inhib- 
itor (cilazapril; 10 “g/kg/day) 
Results: Within 6 weeks of treatment, both drugs showed equipotent effects on blwd 
pressure, left ventricular hypertrophy and fibrosis, synthetic-type myosln heavy chain 
(MHC) NMHC-BiSMemb, and endothelial NO synthase expression in the heart. Furlher- 
more, compared with the vehicle SHRSP group, E4177 showed a greater reduction of 
the wall-to-lumen ratio in rntramyocardial arteries by reducing ROS assessed with iso- 
prostanes and thiobarbituric acid reactive substances by inhibiting NAD(P)H oxidase 
essential subunit p22phox and upregulating CuiZn superoxide dismutase expression, 
and also inhibiting phenotypic modulation by reducing synthetic-type MHC NMHC-A and 
upregulating contractile-type SM-MHC SM2 in the hearI more effectively than did cilaza- 
pril. 
Conclusions: Angiotensin II type-i receptor antagomsts may inhibit vascular remodeling 
and phenotypic change in the heart of SHRSP by reducing ROS via modulation of the 
expression of not only the generating enzymes but also the scavenging enzymes related 
to ROS more efficiently than ACE Inhibitor, and strategies almed at upregulating the 
scavenging enzymes in addition to downregulating the generating enzymes related to 
ROS may have therapeutic potential against vascular remodeling in hypertension. 
1177-130 Endothelial Function and Slow Coronary Flow 
Alps~ Sezqln, Ahmet Sigirci. lrfan Bar&u, Ergun Topal, Nurzen Sezgln, Ramazan 
Ozdemlr, Hakan Gullu, Ertan Yetkin, lzzet Tandogan, Now University, Malatya, Turkey, 
Baskent University, Adana, Turkey 
Objectives-The aim of the study was to determine endothelial function in patients with 
SCF by using flow-mediated dilatation tecmque. 
Background- Slow coronary flow (SCF) in normal coronary angiogram is a well-recog- 
nized cllnical entity, but its etiopathogenesis remans unclear. 
Methods - Coronary flow was quantified using the corrected Thrombosis In Myocardial 
